黏蛋白-1在体外增加肾脏TRPV5活性,且其尿水平与患者钙性肾结石相关
该研究探讨尿黏蛋白-1(MUC1)是否通过增强TRPV5通道活性保护 against 肾结石。在12例高钙尿性肾结石患者中,尿MUC1水平较12例对照显著降低。体外实验表明,野生型MUC1通过半乳凝素-3与TRPV5的N-聚糖形成晶格,抑制TRPV5内吞,从而增加其活性。
要点
- 高钙尿性肾结石患者尿MUC1水平较对照显著降低(n=12 vs n=12)。
- 野生型MUC1增加TRPV5活性,疾病突变型MUC1无此作用。
- MUC1通过半乳凝素-3与TRPV5的N-聚糖结合,抑制其内吞。
核心结论
- MUC1通过半乳凝素-3与TRPV5的N-聚糖形成晶格,抑制TRPV5内吞并增加尿钙重吸收。
- 高钙尿性肾结石患者尿MUC1水平较对照显著降低。
研究设计与样本
- 建立半定量法检测人尿MUC1,比较12例高钙尿性肾结石患者与12例对照。
- 免疫荧光定位MUC1在肾脏的表达。
- 全细胞膜片钳记录HEK细胞中TRPV5活性。
- 免疫共沉淀验证TRPV5与MUC1的物理相互作用。
主要发现
- 与对照(n=12)相比,高钙尿性肾结石患者(n=12)尿MUC1水平显著降低。
- 免疫荧光显示MUC1表达于髓袢升支粗段、远曲小管和集合管。
- 野生型MUC1而非疾病突变型MUC1增加TRPV5活性,通过损害dynamin-2和caveolin-1介导的TRPV5内吞实现。
- 免疫共沉淀证实TRPV5与MUC1存在物理相互作用。
- MUC1未增加N-聚糖缺陷型TRPV5的活性;半乳凝素-3 siRNA而非半乳凝素-1 siRNA阻止MUC1诱导的TRPV5活性上调;缺乏VNTR的MUC1不增加TRPV5活性。
关键数值与推荐
- 高钙尿性肾结石患者(n=12)尿MUC1水平较对照(n=12)显著降低。
- 野生型MUC1增加TRPV5活性,疾病突变型MUC1不增加。
- 半乳凝素-3 siRNA阻止MUC1诱导的TRPV5活性上调,半乳凝素-1 siRNA无此作用。
- 缺乏VNTR的MUC1不增加TRPV5活性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypercalciuria is a major risk factor for nephrolithiasis. We previously reported that Uromodulin (UMOD) protects against nephrolithiasis by upregulating the renal calcium channel TRPV5. This channel is crucial for calcium reabsorption in the distal convoluted tubule (DCT). Recently, mutations in the gene encoding Mucin-1 (MUC1) were found to cause autosomal dominant tubulointerstitial kidney disease, the same disease caused by UMOD mutations. Because of the similarities between UMOD and MUC1 regarding associated disease phenotype, protein structure, and function as a cellular barrier, we examined whether urinary MUC1 also enhances TRPV5 channel activity and protects against nephrolithiasis. We established a semiquantitative assay for detecting MUC1 in human urine and found that, compared with controls (n=12), patients (n=12) with hypercalciuric nephrolithiasis had significantly decreased levels of urinary MUC1. Immunofluorescence showed MUC1 in the thick ascending limb, DCT, and collecting duct. Applying whole-cell patch-clamp recording of HEK cells, we found that wild-type but not disease mutant MUC1 increased TRPV5 activity by impairing dynamin-2- and caveolin-1-mediated endocytosis of TRPV5. Coimmunoprecipitation confirmed a physical interaction between TRPV5 and MUC1. However, MUC1 did not increase the activity of N-glycan-deficient TRPV5. MUC1 is characterized by variable number tandem repeats (VNTRs) that bind the lectin galectin-3; galectin-3 siRNA but not galectin-1 siRNA prevented MUC1-induced upregulation of TRPV5 activity. Additionally, MUC1 lacking VNTRs did not increase TRPV5 activity. Our results suggest that MUC1 forms a lattice with the N-glycan of TRPV5 via galectin-3, which impairs TRPV5 endocytosis and increases urinary calcium reabsorption.
引用
- Nie M, Bal MS, Yang Z, et al. Mucin-1 Increases Renal TRPV5 Activity In Vitro, and Urinary Level Associates with Calcium Nephrolithiasis in Patients. J Am Soc Nephrol. 2016. PMID: 27036738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。